Effect of 2 Years of Testosterone Replacement on Insulin Secretion, Insulin Action, Glucose Effectiveness, Hepatic Insulin Clearance, and Postprandial Glucose Turnover in Elderly Men
- Rita Basu, MD1,
- Chiara Dalla Man, PHD2,
- Marco Campioni, PHD2,
- Ananda Basu, MD1,
- K. Sreekumaran Nair, MD, PHD1,
- Michael D. Jensen, MD1,
- Sundeep Khosla, MD1,
- George Klee, MD, PHD3,
- Gianna Toffolo, PHD2,
- Claudio Cobelli, PHD2 and
- Robert A. Rizza, MD1
- 1Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic College of Medicine, Rochester, Minnestota
- 2University of Padova, Padova, Italy
- 3Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota
- Address correspondence and reprint requests to Robert A. Rizza, MD, Mayo Clinic College of Medicine, 200 1st St. SW, Room 5-194 Joseph, Rochester, MN 55905. E-mail: rizza.robert{at}mayo.edu
Abstract
OBJECTIVE—We sought to determine whether, and if so the mechanism by which, testosterone replacement improves carbohydrate tolerance.
RESEARCH DESIGN AND METHODS—Fifty-five elderly men with relative testosterone deficiency ingested a labeled mixed meal and underwent a frequently sampled labeled intravenous glucose tolerance test before and after either placebo or treatment with testosterone patch (5 mg/day) for 2 years.
RESULTS—Despite restoring bioavailable testosterone to values observed in young men, the change (24 months minus baseline values) in fasting and postprandial glucose, insulin, and C-peptide concentrations and meal appearance, glucose disposal, and endogenous glucose production were virtually identical to those observed after 2 years of placebo. The change over time in insulin and C-peptide concentrations post–intravenous glucose injection also did not differ. Furthermore, the change over time in insulin action and glucose effectiveness (measured with the unlabeled and labeled “oral” and “intravenous” minimal models), as well as insulin secretion and hepatic insulin clearance (measured with the C-peptide model), did not differ in the testosterone and placebo groups.
CONCLUSIONS—We conclude that 2 years of treatment with testosterone in elderly men does not improve carbohydrate tolerance or alter insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, or the pattern of postprandial glucose metabolism. Thus, testosterone deficiency is unlikely the cause of the age-associated deterioration in glucose tolerance commonly observed in elderly men.
Footnotes
-
Published ahead of print at http://care.diabetesjournals.org on 11 May 2007. DOI: 10.2337/dc07-0359.
Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/dc07-0359.
R.A.R. is a consultant for Abbott, Takeda, Symphony Capital, and Eli Lilly and is a member of the scientific advisory boards of Merck, Novo Nordisk, Takeda, and Eli Lilly.
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.
-
- Accepted May 3, 2007.
- Received February 20, 2007.
- DIABETES CARE














